losartan viatris 25 mg filmdragerad tablett
viatris limited - losartankalium - filmdragerad tablett - 25 mg - losartankalium 25 mg aktiv substans; laktosmonohydrat hjälpämne - losartan
losartan viatris 50 mg filmdragerad tablett
viatris limited - losartankalium - filmdragerad tablett - 50 mg - losartankalium 50 mg aktiv substans; laktosmonohydrat hjälpämne - losartan
zolpidem viatris 10 mg filmdragerad tablett
viatris limited - zolpidemtartrat - filmdragerad tablett - 10 mg - laktosmonohydrat hjälpämne; zolpidemtartrat 10 mg aktiv substans - zolpidem
plerixafor viatris 20 mg/ml injektionsvätska, lösning
viatris limited - plerixafor - injektionsvätska, lösning - 20 mg/ml - plerixafor 20 mg aktiv substans
dabigatran etexilate viatris 150 mg kapsel, hård
viatris limited - dabigatranetexilatmesilat - kapsel, hård - 150 mg - propylenglykol hjälpämne; dabigatranetexilatmesilat 172,95 mg aktiv substans
dabigatran etexilate viatris 110 mg kapsel, hård
viatris limited - dabigatranetexilatmesilat - kapsel, hård - 110 mg - dabigatranetexilatmesilat 126,83 mg aktiv substans; propylenglykol hjälpämne
dabigatran etexilate viatris 75 mg kapsel, hård
viatris limited - dabigatranetexilatmesilat - kapsel, hård - 75 mg - dabigatranetexilatmesilat 86,475 mg aktiv substans; propylenglykol hjälpämne
linagliptin viatris 5 mg filmdragerad tablett
viatris limited - linagliptin - filmdragerad tablett - 5 mg - mannitol hjälpämne; linagliptin 5 mg aktiv substans
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiska medel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
bamyl 500 mg brustablett
viatris ab - acetylsalicylsyra - brustablett - 500 mg - acetylsalicylsyra 500 mg aktiv substans; mannitol hjälpämne - acetylsalicylsyra